Argenx SE to raise €637m
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2153 entries already.
Entries by Thomas Gabrielczyk
Recombinant production
Sino Biological specializes in recombinant production of antibodies and proteins. The company routinely conducts high-throughput projects of up to 1,000 per batch. Sino Biological’s manufacturing facility can also handle large-scale production at gram level.
Bayer invests into synthetic TCRs for cell therapy
TCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Bavarian Nordic bags $225m for licence to RSV vaccine
Bavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese commercialisation rights for MVA-BN® RSV to Nuance Pharma.
RTSM benefits: configuration versus customisation
In the 1990s, the first clinical IVR systems (Interactive Voice Response Systems) were developed in order to randomise patients over the phone, and later, to dispense drug and resupply sites as well.
Switzerland paves the way for genome editing
Switzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV launches €517m
Gilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.
Precirix NV raises €80m in Series B financing
With €80m from a Series B financing in its pocket, Belgian Precirix NV plans to advance its pipeline of precision radiopharmaceuticals.
Sanofi bags €300m from US investor Blackstone
Sanofi has secured money from Blackstone Life Sciences to speed up development of its daratumumab competitor isatuximab in multiple myeloma.
Life-sciences hub Saxony: a driver of innovation for cell and gene therapy
Saxony has established itself as a dynamic life-sciences hub and provides an attractive environment for investors and start-ups The SaxoCell’ network and CMI major research centre are furthering innovations in cell and gene therapy Interdisciplinary co-operation offers huge growth opportunities for applications such as point-of-care diagnostics Leipzig as host of BIO-Europe 2022